Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. One equities research analyst has rated the stock with a Buy rating. Based on data from MarketBeat, Oramed Pharmaceuticals currently has an average rating of “Buy”.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP stock opened at $3.86 on Friday. Oramed Pharmaceuticals has a 1 year low of $2.09 and a 1 year high of $5.47. The firm has a market capitalization of $160.58 million, a PE ratio of 0.94 and a beta of 1.31. The stock has a fifty day moving average of $4.46 and a two-hundred day moving average of $4.04.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). Equities research analysts predict that Oramed Pharmaceuticals will post 1.47 earnings per share for the current fiscal year.

Insider Activity at Oramed Pharmaceuticals

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $90,200.00. Following the completion of the sale, the chief financial officer directly owned 861,076 shares in the company, valued at $3,883,452.76. This represents a 2.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $135,300.00. Following the transaction, the chief operating officer directly owned 1,328,130 shares of the company’s stock, valued at approximately $5,989,866.30. The trade was a 2.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.77% of the stock is owned by insiders.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ORMP. BML Capital Management LLC raised its holdings in Oramed Pharmaceuticals by 2.1% during the 3rd quarter. BML Capital Management LLC now owns 884,392 shares of the biotechnology company’s stock worth $4,130,000 after buying an additional 18,123 shares during the period. Engineers Gate Manager LP purchased a new stake in Oramed Pharmaceuticals during the second quarter valued at about $61,000. Bank of New York Mellon Corp purchased a new stake in Oramed Pharmaceuticals during the second quarter valued at about $381,000. Bank of America Corp DE boosted its holdings in shares of Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after buying an additional 3,909 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Oramed Pharmaceuticals in the first quarter worth about $63,000. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company’s proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed’s development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.